Alessandro Rametta

4 febbraio – Giornata mondiale contro il cancro. Prevenzione, vaccinazioni e screening riducono il rischio oncologico e permettono diagnosi precoci. Sono strumenti semplici e disponibili, che possono fare la differenza.

Machine Learning to predict response to IO in 438 patients with metastatic urothelial carcinoma from Italian @meeturoIT network. Results are exploratory but clinically coherent. AI can play an important role in GU oncology. Better data quality and wider implementation of these approaches are essential. Thanks to @PrelajArsela, @polimi and all the @AI_ON_Lab for this work. @giannatempopatr @g_procopio_ @marcos130990 @AndreaNecchi @Vanja_Miskovic_ Out on ESMO RWD and DO: sciencedirect.com/science/articl…

Innovation talk at @IstTumori with @alerametta: machine learning and artificial intelligence in GU tumors, how data and algorithms can improve diagnosis and treatment. #AIinMedicine #ClinicalResearch #Oncology #Genitourinary #ScientificEvent #ControversiesinGU2026

A full day of debate, evidence and shared perspectives comes to an end at @IstTumori. Thank you to all speakers, participants and partners for contributing to "Controversies in Genitourinary Tumors". See you next year! #ClinicalResearch #GUoncology #ControversiesinGU2026

How do we actually treat non–clear cell RCC today? Our practical overview of systemic therapies across rare renal cancer histologies. tandfonline.com/eprint/FKBUJ3X… @g_procopio_ @elena_verzoni @marcos130990 @MelClaps @valentina79g @nzzmda @Simorota6 @elegusma

A review in @NatRevClinOncol @scocmem covers whats next for FGFR in bladder cancer. FORAGER-2 explores EV + pembro + Vepugratinib (FGFR inhibitor with short half life) in 1st line FGFR3 altered advanced UC. Targeted/ADC/PD1 triplets curing UC? @OncoAlert @DrChoueiri @PGrivasMDPhD

#ESMO25 #MIBC #BladderCancer ➡️ Perioperative Pembro + EV. 😶 No words. 👏🏼 Just applause. 📣 Sound On. @myESMO

1/2 Disitimab Vedotin & toripalimab beating platinum chemotherapy in 1st line UC in HER2 +ves. HRs for PFS/OS =0.36/0.56 respectively. RR and CR rate of 76% & 5% respectively. Tox related discontinuation in 12 vs 10% respectively. Working across all subsets #ESMO25 @OncoAlert

📢 Our case report on metastatic Leydig cell tumor treated with CDK4 inhibition is now published in JCO Precision Oncology! 👉 doi.org/10.1200/PO-25-… A collaborative effort with @JCOPO_ASCO @giannatempopatr @nicolanicolai @AndreaNecchi @montypal

IMvigor011 𝗰𝘁𝗗𝗡𝗔+ → 𝗢𝗦/𝗣𝗙𝗦 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝘄𝗶𝘁𝗵 𝗮𝘁𝗲𝘇𝗼 𝗰𝘁𝗗𝗡𝗔– → 𝘀𝗽𝗮𝗿𝗲𝗱 𝘂𝗻𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 𝗜𝗢 Primum non nocere: treating only those with molecular evidence of disease. This is Huge! Congrats to @tompowles1 and everyone involved 👏

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

The +ve periopertive EVP trial for OS in cis ineligible MIBC may open a new area. Especially if its like EVP in M1 disease. 3 more trials in this area are awaited which test 1) EVP vs cisplatin (NIAGARA population), 2) EV/PD1/CTLA4 vs surgery 3) treatment based on ctDNA status.

Today, serum KIM-1 is the biomarker to explore in all stages of RCC, via @eufocus pubmed.ncbi.nlm.nih.gov/40619332/

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. @brian_rini @OncoAlert

Today is #WorldKidneyCancerDay! To mark the occasion, @IstTumori is hosting a special event for patients about genitourinary cancers: a space for support, information, and connection. #KidneyCancer #GUcancer #Oncology #PatientSupport

Current status of adiuvant #immunotherapy in #RCC: a Delphi study coordinated by Bernard Escudier. Full article here: doi.org/10.1016/j.ejca… #CancerResearch #oncology #genitourinary #RCC #Immunotherapy

Breaking news @ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall @AttardLab @PCF_Science @urotoday @OncoAlert

Just back from #ASCO25, where I joined an @ecancer roundtable on recent updates in renal cell carcinoma. Great to exchange views with highly experienced colleagues in the field. 🎥 Video here: player.vimeo.com/video/10898609… @g_develasco @MikeSerzanMD @docjavip #GUcancer #RenalCancer

The #ASCO25 #OncoAlertTOP10 Abstracts in #GUOncology These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago 🇺🇸 #ProstateCancer #BladderCancer #kidneyCancer ⭐Abs 4518 SURE-02: NEOADJUVANT SACITUZUMAB GOVITECAN PLUS PEMBROLIZUMAB, FOLLOWED BY RESPONSE-ADAPTED BLADDER SPARING AND ADJUVANT PEMBRO, IN MUSCLE-INVASIVE BLADDER CANCER ⭐Abs 4521 AREN1721: AXITINIB+NIVOLUMAB COMBINATION THERAPY VS. SINGLE AGENT NIVOLUMAB FOR THE TREATMENT OF TFE/TRANSLOCATION RENAL CELL CARCINOMA ACROSS ALL AGE GROUPS ⭐Abs 5000 CAN-2409+PRODRUG IN COMBINATION WITH STANDARD OF CARE EXTERNAL BEAM RADIATION (EBRT) FOR NEWLY DIAGNOSED LOCALIZED PROSTATE CANCER ⭐Abs LBA5006 SUNRISE-4: TAR-200 + CETRELIMAB OR CET ALONE AS NEOADJUVANT THERAPY IN MUSCLE-INVASIVE BLADDER CANCER INELIGIBLE FOR OR REFUSE NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY ⭐Abs 5019 TALAPRO-2: HOMOLOGOUS RECOMBINATION REPAIR ALTERATIONS BY GENE SUBGROUP AND POTENTIAL ASSOCIATIONS WITH EFFICACY IN THE HRR-DEFICIENT POPULATION ⭐Abs 4500 CHECKMATE 901 PHASE 3 TRIAL: IPI/NIVO VS GEM/CARBO AS 1L THERAPY IN CISPLATIN-INELIGIBLE PATIENTS WITH MUC ⭐Abs 4514 FIVE-YEAR FOLLOW-UP KEYNOTE-564 STUDY OF ADJUVANT PEMBROLIZUMAB (PEMBRO) FOR THE TREATMENT OF CLEAR CELL RENAL CELL CARCINOMA ⭐Abs 4516 PDIGREE (ALLIANCE A031704): IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA (MCCRCC) ⭐Abs 4517 CREST: SASANLIMAB IN COMBINATION WITH BACILLUS CALMETTE-GUÉRIN (BCG) IN BCG-NAIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): EVENT-FREE SURVIVAL (EFS) ⭐Abs 4506 COMBINATION CASDATIFAN PLUS CABOZANTINIB EXPANSION COHORT OF PHASE 1 ARC-20 STUDY IN PREVIOUSLY TREATED PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA ⭐Abs LBA4513 ENLIGHTED INTERIM RESULTS OF EFFICACY AND SAFETY OF PADELIPORFIN VASCULAR TARGETED PHOTODYNAMIC THERAPY IN TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER ⭐Abs 4520 CLONEVO: PREOPERATIVE ABEMACICLIB FOR CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER (MIBC) WITH MOLECULAR RESPONSE ASSESSMENT ⭐Abs LBA5012 AN OPEN LABEL RANDOMIZED NON-INFERIORITY TRIAL COMPARING ADJUVANT PLATINUM PLUS PACLITAXEL TO PLATINUM PLUS 5-FU AFTER CURATIVE RESECTION IN HIGH-RISK PENILE CARCINOMA Lead @nataliagandur @ReginaBarCar @yekeduz_emre @weoncologists Faculty: @apolo_andrea @DrChoueiri @PGrivasMDPhD @ravikanesvaran @neerajaiims @amerseburger @drenriquegrande @Silke_Gillessen Ping GU Faculty @montypal @crisbergerot @DrDanielHeng @DrChoueiri @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @DrYukselUrun #OncoAlertAF @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

ESMO drop just crashed the site. Clinicians, researchers, and oncologists everywhere hitting refresh like it’s Taylor Swift ticket day. Science waits for no server. #ESMO25 #Oncology #CancerResearch #ESMOAbstracts #ESMOcrash @alerametta @elegusma @Simorota6 @myESMO @AIOMtweet